HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natural Remedies Sales Growth Outpaces OTC Drugs – Study

This article was originally published in The Rose Sheet

Executive Summary

Sales of natural consumer health products, often used to treat the same ailments as OTC drugs, are growing as consumer interest increases in products formulated for prevention and the population ages, says Kline Market Research.

You may also be interested in...



Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”

Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.

Washington State Continues Taking Cues From California; Toxic-Free Cosmetics Act Is Back

Washington State’s Toxic-Free Cosmetics Act would ban use of any and all PFAS, matching work California started in 2020 and finished with legislation enacted last year. It also would blacklist ortho-phthalates, formaldehyde, methylene glycol and any other chemical determined by the department to release formaldehyde, among other deemed hazardous substances.

US Modernized Cosmetics Law’s ‘Weak’ Safety Substantiation Standard Leaves NGOs Wanting

Breast Cancer Prevention Partners and its Campaign for Safe Cosmetics, along with the Environmental Working Group and Women’s Voices for the Earth, see the US Modernization of Cosmetics Regulations Act of 2022 as a significant jump forward. But its “sweeping” preemption provisions could put consumers at risk, and its cosmetics safety substantiation standard is a step back from preexisting FDA regulations, the groups say.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel